Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorPrisma Health-Upstate
About this trial
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Eligibility criteria
Qualifiers
Age ≥21 years
Smoke ≥5 CPD for ≥1 year
Daily CC smoker
Willing to switch to EC
Disqualifiers
Interested in quitting CC (contemplation stage of change)
Use of EC on ≥4 of the past 30 days
Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days
Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days
Trial design
Treatments tested in this trial
- Brief individual counseling sessions
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Prisma Health-Upstate
Lead sponsor
Clemson University
Sponsor institution
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov